Successful Treatment of Pump Thrombosis with Tirofiban in the Setting of Acute Renal Insufficiency

Introduction: Left ventricular assist devices (LVAD) have become the standard of care for end stage cardiomyopathy, as destination therapy (DT) or bridge to transplant (BTT). Pump thrombosis is a potentially life threatening complication with incidence up to 13%. Guidelines recommend use of intravenous anticoagulation, thrombolytics, antiplatelet therapy, pump exchange or a combination thereof. Eptifibatide is renally excreted, therefore contraindicated in end stage renal disease, whereas tirofiban, due to high protein binding and 25% fecal elimination, can still be utilized.

Source: Journal of Cardiac Failure - August 1, 2017 Category: Cardiology Authors: Khansa Ahmad, George Gavrilos, Tisha Suboc, Karen Meehan, Natalie Cora, Sunil Puawaa, Gregory Macaluso, Ambar Andrade, William Cotts Source Type: research